Longevity-focused skin care OneSkin has closed a series A investment round, led by Selva Ventures, as well as PLUS Capital, Unilever Ventures, Able Partners, and former investors SOSV and Meta Planet, bringing the brand's total funding to $20 million.
The new funding will, unsurprisingly, be applied toward the brand's next phase of growth, including formula R&D, new hiring and expansion into new sales channels.
Additional investors in the four-year-old brand include Brazilian-American model and designer, Camila Alves McConaughey, from PLUS Capital's collective of artist and athlete partners, and tech entrepreneur Kevin Rose (Dogg, Milk, etc.).
Earlier this year, Carolina Reis Oliveira, Ph.D., OneSkin co-founder and CEO, spoke with Global Cosmetic Industry about the underserved Gen X consumer and the brand's mission of bringing longevity beauty mainstram.
Oliveira noted, "There’s a frustration amongst this consumer with the overwhelm of anti-aging messaging. And it makes sense, beauty at large uses youthful slogans and visuals to showcase product efficacy. When in fact, if we dive deeper—what this consumer really cares about is vitality, longevity and they dislike? Being spoken down to. Instead, we aim to arm and empower with information."
OneSkin's Core Senescence-blocking Peptide
To deliver on aging consumers' healthy skin needs, the brand has been built around acore ingredient, OS-01.
Per the brand, the OS-01 senescence blocking peptide is designed to reverse biological aging at the cellular level by targeting existing aging (accumulated senescent cells) while also providing a trifecta of protection from UV, collagen breakdown and skin aging.
Funding Fueling Innovation at OneSkin
Of the investment news, Oliveira says, "At OneSkin, we are excited to announce this new round of funding, which will further drive our mission to transform how we think about our skin, not only by optimizing our aesthetics using cutting-edge science, but also focusing on its functional role as our largest organ and the impact in our overall health and longevity."
Alessandra Zonari, Ph.D., cofounder and CSO of OneSkin, adds, "This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate aging at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin. We are dedicated to advancing the future of skin health with the most advanced longevity research and innovation."
McConaughey notes, "As a Brazilian woman, I am thrilled to invest in a brand founded by four Brazilian female scientists–my heritage is something I'm incredibly proud of, and I am honored to support those who are executing this work. The OneSkin team has built a line of products that hold a unique space in the massive skin care market. I fell in love with the products the moment I saw the results on myself, and I knew I had to be a part of it! I'm so looking forward to seeing their future innovations and continued success with the help of this funding."
"After working with the OneSkin team over the past two years, we are thrilled to deepen our partnership by leading their Series A round," says Madeline Kaplan, partner at Selva Ventures. "This is our firm's largest investment, reflecting our high conviction in the company and the team, led by Carolina and Alessandra. We are seeing the beauty and wellness spaces converge as more consumers want efficacious products that make them look and feel their best. OneSkin is well-positioned at the intersection of beauty and wellness, delivering exceptional results that improve both skin appearance and skin health."
